Forge Therapeutics Inc, a company developing novel antibiotics targeting bacterial metalloenzymes, has signed a research collaboration and option agreement with Switzerland-based Hoffmann-La Roche Ltd, to license FG-LpxC LUNG, a novel antibiotic intended for the treatment of serious lung infections attributed to antibiotic-resistant Gram-negative bacteria including Pseudomonas aeruginosa, it was reported on Wednesday.
The FG-LpxC LUNG program is intended to treat hospital-based infections, including those cited on the CDC's most urgent threats list that commonly occur in people with weakened immune systems and chronic lung diseases.
According to the terms of the contract, Hoffmann-La Roche Ltd has an exclusive option to license the FG-LpxC LUNG program from Forge. Forge will retain control of the program prior to Roche exercising its option, at which time Roche will take over the further development. Forge is eligible to receive up to USD190.5m in total payments, including potential sales-based payments and royalties upon commercialisation of the program.
GSK releases decade-long data on Shingrix efficacy
GSK announces positive EAGLE-1 results for gepotidacin in gonorrhoea treatment
Boehringer Ingelheim reports strong growth in 2023 and accelerates late-stage pipeline
Charles River Laboratories launches AMAP to reduce animal testing reliance
PureTech completes enrollment in Phase 2b ELEVATE IPF trial for LYT-100
Cybin secures additional US patent for CYB003 breakthrough therapy programme
UroGen's UGN-103 IND accepted by FDA for bladder cancer treatment
Biophytis reinforces obesity IP with new patent application
MaaT Pharma reveals positive 18-month data for MaaT013 in GI-aGvHD
Fusion Antibodies plc secures contract for OptiPhage library development
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients